Corina Schneidawind

Years Active: 2019-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Estelle Erkner, Thomas Hentrich, Rebekka Schairer, Rahel Fitzel, Kathy-Ann Secker-Grob, Johan Jeong, Hildegard Keppeler, Fulya Korkmaz, Julia M Schulze-Hentrich, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia. Oncogene (2023)
Kathy-Ann Secker, Lukas Bruns, Hildegard Keppeler, Johan Jeong, Thomas Hentrich, Julia M Schulze-Hentrich, Barbara Mankel, Falko Fend, Dominik Schneidawind, Corina Schneidawind
Only Hematopoietic Stem and Progenitor Cells from Cord Blood Are Susceptible to Malignant Transformation by MLL-AF4 Translocations. Cancers 12 (6) (2020)
Kathy-Ann Secker, Bianca Bloechl, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, Dominik Schneidawind, Johan Jeong, Thomas Hentrich, Julia M Schulze-Hentrich, Corina Schneidawind
MAT2A as Key Regulator and Therapeutic Target in MLLr Leukemogenesis. Cancers 12 (5) (2020)
Corina Schneidawind, Simona Jahnke, Irmtraud Schober-Melms, Michael Schumm, Rupert Handgretinger, Christoph Faul, Lothar Kanz, Wolfgang Bethge, Dominik Schneidawind
G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. British journal of haematology 186 (1) (2019)

Corina Schneidawind.css-eqlu8i{font-size:small;padding-left:4px;}